Reduced responsiveness to the anti-inflammatory effects of corticosteroids is a major barrier
to effective management of asthma in smokers and patients with severe asthma and in the …

Glucocorticoid resistance or insensitivity is a major barrier to the treatment of several
common inflammatory diseases—including chronic obstructive pulmonary disease and …

BACKGROUND: Eosinophilic airway inflammation is heterogeneous in asthmatic patients.
We recently described a distinct subtype of asthma defined by the expression of genes …

1. Glucocorticoids are widely used for the suppression of inflammation in chronic
inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disease …

Rationale: The role of airway microbiome in corticosteroid response in asthma is unknown.
Objectives: To examine airway microbiome composition in patients with corticosteroid …

Background TH 2 cells can further differentiate into dual-positive TH 2/TH 17 cells. The
presence of dual-positive TH 2/TH 17 cells in the airways and their effect on asthma severity …

Pulmonary fibrosis is a chronic lung disease characterized by excessive accumulation of
extracellular matrix (ECM) and remodeling of the lung architecture. Idiopathic pulmonary …

Our understanding of asthma has evolved over time from a singular disease to a complex of
various phenotypes, with varied natural histories, physiologies, and responses to treatment …

Glucocorticoids are the most effective anti‐inflammatory therapy for asthma yet are relatively
ineffective in chronic obstructive pulmonary disease. Glucocorticoids suppress inflammation …

The mechanisms associated with the development of severe, corticosteroid (CS)-dependent
asthma are poorly understood, but likely heterogenous. It was hypothesized that severe …